Sat Jan 11 15:50:00 UTC 2025: ## Indian CRISPR Research Hampered by Patent Restrictions: Farmers Miss Out on Biotech Benefits
**Hyderabad, India – January 12, 2025** – A new report reveals that Indian researchers can only use the groundbreaking CRISPR-Cas9 gene-editing technology for academic purposes, hindering commercial applications and leaving farmers without access to potential biotechnological advancements.
While CRISPR-Cas9, a revolutionary gene-editing tool developed by Drs. Jennifer Doudna and Emmanuelle Charpentier (Nobel laureates), holds immense promise for improving crop yields and treating diseases, a local patent granted to ERS Genomics limits its use in India. This restriction, highlighted in a report by Dr. Anurag Chaurasia, prevents Indian scientists from commercializing their research, keeping crucial agricultural breakthroughs out of the hands of farmers.
The technology, which allows for precise modifications to DNA, has already shown success in various fields. International researchers have used CRISPR-Cas9 to develop cancer mouse models, identify genes impacting cancer drug effectiveness, and modify immune cells. Agricultural applications have also yielded promising results, such as increasing the sweetness of tomatoes without affecting their weight. In India, scientists at the LV Prasad Eye Institute have successfully used similar gene editing techniques to correct inherited mutations in stem cells, opening doors for new therapies for eye disorders.
However, the current patent situation effectively prevents Indian scientists from translating these promising developments into commercial products, leaving Indian agriculture reliant on traditional methods. This limitation contrasts sharply with the global progress made using CRISPR-Cas9, highlighting the urgent need for policy changes to enable Indian researchers and farmers to benefit from this powerful technology.
First Piper 